Fábio Munhoz Svartman

Fábio Munhoz Svartman

Auto-generated profile, based on publicly available information

Fábio Munhoz Svartman

Hospital Nossa Senhora da Conceição, Porto Alegre (RS) Brasil

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2022 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
FSFábio Munhoz Svartman
Fábio Munhoz Svartman
MLMaurício Mello Roux Leite
Maurício Mello Roux Leite
ASAna Paula Garcia Sartori
Ana Paula Garcia Sartori
RGRenato Soares Gutierrez
Renato Soares Gutierrez
ACAna Carolina Cadore
Ana Carolina Cadore
CACristiano Feijó Andrade
Cristiano Feijó Andrade
Objective: To describe the performance of a pulmonologist-led lung cancer screening pro-gram using low dose CT (LDCT) in a cohort of outpatients with stable respiratory diseases in the Brazilian public health care system. Methods: This was a retrospective analysis of the first two rounds of lung cancer screening of patients enrolled in the program. Inclusion criteria were being between 55 and 80 years of age, being a current or former smoker (smoking cessation = 15 years), and having a smoking history = 30 pack-years. LDCT results were interpreted in accordance with the Lung CT Screening Reporting and Data System, and those with a score of 3 or 4 were considered posi-tive screening. Incidental pleuropulmonary findings were sought in all reports. Results: LDCTs were requested for 791 patients during the study period, and 712 patients (90%) met the screening criteria. The mean patient age was 63 years, and most participants were current smokers (56%) with emphysema (78.5%) and other pleuropulmonary findings on CT (64%). Screening was positive in 14.0% and 5.6% of the cases in the first and second screening rounds, respectively. Lung cancer was detected in 1.5% of the patients in both first and second rounds (positive predictive value: 11.0% and 26.6%, respectively). The rate of early-stage (TNM I or II) screen-detected non-small cell carcinoma was 64.3%. Of the patients with positive screening, 19% were lost to follow-up before investigation was complete. Conclusions: The results of this screening program suggest its adequate performance in a cohort of patients with significant respiratory morbidity. The loss to follow-up rate highlights the need for constant monitoring and interventions to ensure adherence.

25 November 2024 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
FSFábio Munhoz Svartman
Fábio Munhoz Svartman
MAMarina Ilha de Azambuja
Marina Ilha de Azambuja
EPEduarda de Albuquerque Palma
Eduarda de Albuquerque Palma
ASAna Paula Garcia Sartori
Ana Paula Garcia Sartori
MLMaurício Mello Roux Leite
Maurício Mello Roux Leite

1 January 2019 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
PDF file
HOHugo Goulart de Oliveira
Hugo Goulart de Oliveira
DODiogo Martins de Oliveira
Diogo Martins de Oliveira
CGCamila Greggianin
Camila Greggianin
CACristiano Feijó Andrade
Cristiano Feijó Andrade
FSFábio Munhoz Svartman
Fábio Munhoz Svartman
Figure 1. In A, stenosis of the left main bronchus. In B, the biodegradable stent after placement. In C, the site of bronchial stenosis after 16 months of follow-up.